RxDoctor Payments Data

Nengchun Huang, MD

Neurology · Los Gatos, CANPI 1740212547

Payments from drug & device makers

$83,968in general payments, 2019–2025

Across 1,387 payments — averaging $60.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$20K
  • MDD US Operations, LLC$15K
  • Acorda Therapeutics, Inc$12K
  • Boston Scientific$12K
  • AbbVie$5K
  • Teva Pharmaceuticals USA, Inc.$2K
  • plus $17K from 30 others
$6,997in research payments, 2019–2025

Across 1 payment — averaging $6996.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Neurocrine Biosciences, Inc.$7K

What the payments were for

  • Consulting fees$9,55011%
  • Speaking & faculty fees$31,58438%
  • Travel & lodging$7,6399%
  • Food & beverage$34,45741%
  • Education$7371%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$83,968 in reported general payments places this provider in the 85th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$710,114
Medicare patients
553
Services billed
23,263

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RytaryCarbidopa/Levodopa1,439$1,328,038
ApokynApomorphine Hcl15$324,782
NuplazidPimavanserin Tartrate48$288,363
GocovriAmantadine Hcl103$228,932
NourianzIstradefylline34$84,667
Carbidopa-LevodopaCarbidopa/Levodopa1,215$47,911
NeuproRotigotine39$41,300
Ropinirole ErRopinirole Hcl246$39,233
Entacapone164$33,067
GemtesaVibegron48$28,641
XadagoSafinamide Mesylate22$26,326
AmantadineAmantadine Hcl553$20,436
OngentysOpicapone20$18,158
MyrbetriqMirabegron24$16,690
Pramipexole ErPramipexole Di-Hcl30$14,531

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Amneal Pharmaceuticals LLCRytary$1,261$1,328,0381,439 claims
Acadia Pharmaceuticals IncNuplazid$2,299$288,36348 claims
MDD US Operations, LLCGocovri$14,637$228,932103 claims
Kyowa Kirin, Inc.Nourianz$1,341$84,66734 claims
UCB, Inc.Neupro$1,189$41,30039 claims
Neurocrine Biosciences, Inc.Ongentys$19,626$18,15820 claims
AbbVieBotox$4,865$13,19021 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,996 neurology providers in California.

Other neurology in Los Gatos

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →